REM-422

Phase 2Small molecule

RRemix Therapeutics

REM-422 is one of 50 small molecule programs targeting Adenoid Cystic Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adenoid Cystic CarcinomaRecruiting

Myelodysplastic SyndromesRecruiting

Adenoid Cystic CarcinomaPhase 2

Recruiting

Myelodysplastic SyndromesPhase 1

Recruiting

Competition

Competitive Landscape

41 competitors in Myelodysplastic Syndromes

#DrugCompanyPhaseTrials

Dacogen

Sun Pharmaceutical Industries, Inc.

Approved

18 2

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

38 3

Cytosar

Teva

Approved

13 4

Idamycin

Pfizer

Approved

6 5

Reblozyl

Bristol-Myers Squibb

Phase 3

15 6

Evrenzo

Astellas

Phase 3

2 7

Xospata

Astellas

Phase 3

1 8

Rytelo

Fludara

5 10

Arava

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalRecruiting

Adenoid Cystic Carcinoma

NCT06118086

Q1 2028

Phase 1Recruiting

Myelodysplastic Syndromes

NCT06297941

Clinical

Trials by Indication[1]

Myelodysplastic Syndromes1 trial

A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS

Recruiting·RRemix Therapeutics·Phase 1·NCT06297941·100 enrolled

Adenoid Cystic Carcinoma1 trial

A Phase 1/2, Multicenter, Open-label Study of REM-422, a MYB mRNA Degrader, in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma

Recruiting·RRemix Therapeutics·Preclinical·NCT06118086·125 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for REM-422. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REM-422 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REM-422. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Remix Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRemix Therapeutics

REM-422

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2028

Trials by Indication[1]

Myelodysplastic Syndromes1 trial

Adenoid Cystic Carcinoma1 trial

References

Drug Info

Quick Facts

Related News